Effects of Psychiatric Drugs on Blood Pressure

Morreale MK, Wake LA. Psychiatric Medications and Hypertension. Current hypertension reports. 2020;22(11):86. doi: 10.1007/s11906-020-01096-4

Chu A, Wadhwa R. Selective Serotonin Reuptake Inhibitors. StatPearls. Treasure Island (FL)2023.

Lespérance F, Frasure-Smith N, Koszycki D, et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. Jama. 2007;297(4):367-79. doi: 10.1001/jama.297.4.367

Zhong Z, Wang L, Wen X, et al. A meta-analysis of effects of selective serotonin reuptake inhibitors on blood pressure in depression treatment: outcomes from placebo and serotonin and noradrenaline reuptake inhibitor controlled trials. Neuropsychiatric disease and treatment. 2017;13:2781-96. doi: 10.2147/ndt.s141832

Sansone RA, Sansone LA. Serotonin norepinephrine reuptake inhibitors: a pharmacological comparison. Innovations in clinical neuroscience. 2014;11(3-4):37-42. doi:

Arakawa R, Stenkrona P, Takano A, et al. Venlafaxine ER Blocks the Norepinephrine Transporter in the Brain of Patients with Major Depressive Disorder: a PET Study Using [18F]FMeNER-D2. The international journal of neuropsychopharmacology. 2019;22(4):278-85. doi: 10.1093/ijnp/pyz003

Debonnel G, Saint-André E, Hébert C, et al. Differential physiological effects of a low dose and high doses of venlafaxine in major depression. The international journal of neuropsychopharmacology. 2007;10(1):51-61. doi: 10.1017/s1461145705006413

Low Y, Setia S, Lima G. Drug–drug interactions involving antidepressants: focus on desvenlafaxine. Neuropsychiatric disease and treatment. 2018;14:567-80. doi: 10.2147/NDT.S157708

Munoli RN, Praharaj SK, Bhandary RP, et al. Desvenlafaxine-induced worsening of hypertension. The Journal of neuropsychiatry and clinical neurosciences. 2013;25(2):E29-30. doi: 10.1176/appi.neuropsych.12030074

Lambert O, Bourin M. SNRIs: mechanism of action and clinical features. Expert review of neurotherapeutics. 2002;2(6):849-58. doi: 10.1586/14737175.2.6.849

Asnis GM, Henderson MA. Levomilnacipran for the treatment of major depressive disorder: a review. Neuropsychiatric disease and treatment. 2015;11:125-35. doi: 10.2147/ndt.s54710

Calvi A, Fischetti I, Verzicco I, et al. Antidepressant Drugs Effects on Blood Pressure. Frontiers in cardiovascular medicine. 2021;8:704281. doi: 10.3389/fcvm.2021.704281

Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. British Journal of Pharmacology. 2007;151(6):737-48. doi: https://doi.org/10.1038/sj.bjp.0707253

Schoenberger JA. Drug-induced orthostatic hypotension. Drug safety. 1991;6(6):402-7. doi: 10.2165/00002018-199106060-00002

Taylor WD. Depression in the Elderly. New England Journal of Medicine. 2014;371(13):1228-36. doi: 10.1056/NEJMcp1402180

Darowski A, Chambers SA, Chambers DJ. Antidepressants and falls in the elderly. Drugs & aging. 2009;26(5):381-94. doi: 10.2165/00002512-200926050-00002

Rabkin JG, Quitkin FM, McGrath P, et al. Adverse reactions to monoamine oxidase inhibitors. Part II. Treatment correlates and clinical management. Journal of clinical psychopharmacology. 1985;5(1):2-9. doi:

Sunderland T, Cohen RM, Molchan S, et al. High-dose selegiline in treatment-resistant older depressive patients. Archives of general psychiatry. 1994;51(8):607-15. doi: 10.1001/archpsyc.1994.03950080019003

Delini-Stula A, Baier D, Kohnen R, et al. Undesirable blood pressure changes under naturalistic treatment with moclobemide, a reversible MAO-A inhibitor--results of the drug utilization observation studies. Pharmacopsychiatry. 1999;32(2):61-7. doi: 10.1055/s-2007-979193

Stage KB. Orthostatic side effects of clomipramine and moclobemide during treatment for depression. Nordic journal of psychiatry. 2005;59(4):298-301. doi: 10.1080/08039480500213725

Korn A, Eichler HG, Fischbach R, et al. Moclobemide, a new reversible MAO inhibitor--interaction with tyramine and tricyclic antidepressants in healthy volunteers and depressive patients. Psychopharmacology. 1986;88(2):153-7. doi: 10.1007/bf00652232

Katona C, Bercoff E, Chiu E, et al. Reboxetine versus imipramine in the treatment of elderly patients with depressive disorders: a double-blind randomised trial. Journal of affective disorders. 1999;55(2-3):203-13. doi: 10.1016/s0165-0327(99)00073-7

Fossa AA, Wisialowski TA, Cremers T, et al. Improved preclinical cardiovascular therapeutic indices with long-term inhibition of norepinephrine reuptake using reboxetine. Toxicology and applied pharmacology. 2012;264(3):343-50. doi: 10.1016/j.taap.2012.09.010

Teply RM, Packard KA, White ND, et al. Treatment of Depression in Patients with Concomitant Cardiac Disease. Progress in Cardiovascular Diseases. 2016;58(5):514-28. doi: https://doi.org/10.1016/j.pcad.2015.11.003

Balit CR, Lynch CN, Isbister GK. Bupropion poisoning: a case series. Medical Journal of Australia. 2003;178(2):61-3. doi: https://doi.org/10.5694/j.1326-5377.2003.tb05064.x

Anttila SA, Leinonen EV. A review of the pharmacological and clinical profile of mirtazapine. CNS drug reviews. 2001;7(3):249-64. doi: 10.1111/j.1527-3458.2001.tb00198.x

de Jonge P, Honig A, van Melle JP, et al. Nonresponse to treatment for depression following myocardial infarction: association with subsequent cardiac events. The American journal of psychiatry. 2007;164(9):1371-8. doi: 10.1176/appi.ajp.2007.06091492

Fagiolini A, Comandini A, Catena Dell'Osso M, et al. Rediscovering trazodone for the treatment of major depressive disorder. CNS Drugs. 2012;26(12):1033-49. doi: 10.1007/s40263-012-0010-5

Camacho LD, Stearns J, Amini R. Management of Trazodone Overdose with Severe Hypotension. Case Reports in Emergency Medicine. 2019;2019:2470592. doi: 10.1155/2019/2470592

Mago R, Tripathi N, Andrade C. Cardiovascular adverse effects of newer antidepressants. Expert review of neurotherapeutics. 2014;14(5):539-51. doi: 10.1586/14737175.2014.908709

Sahli ZT, Banerjee P, Tarazi FI. The Preclinical and Clinical Effects of Vilazodone for the Treatment of Major Depressive Disorder. Expert Opinion on Drug Discovery. 2016;11(5):515-23. doi: 10.1517/17460441.2016.1160051

Sanchez C, Asin KE, Artigas F. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacology & therapeutics. 2015;145:43-57. doi: 10.1016/j.pharmthera.2014.07.001

Baldwin DS, Chrones L, Florea I, et al. The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies. Journal of psychopharmacology (Oxford, England). 2016;30(3):242-52. doi: 10.1177/0269881116628440

Behlke LM, Lenze EJ, Carney RM. The Cardiovascular Effects of Newer Antidepressants in Older Adults and Those With or At High Risk for Cardiovascular Diseases. CNS Drugs. 2020;34(11):1133-47. doi: 10.1007/s40263-020-00763-z

Doherty T, Wajs E, Melkote R, et al. Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program. CNS Drugs. 2020;34(3):299-310. doi: 10.1007/s40263-020-00699-4

Bahr R, Lopez A, Rey JA. Intranasal Esketamine (Spravato(TM)) for Use in Treatment-Resistant Depression In Conjunction With an Oral Antidepressant. P & T : a peer-reviewed journal for formulary management. 2019;44(6):340-75. doi:

Lakshmikuttyamma A, Hajjar E, Henley C, et al. Chapter 2 - Antipsychotic agents. In: Ray SD, editor. Side Effects of Drugs Annual. 44: Elsevier; 2022. p. 7-16.

Pillinger T, McCutcheon RA, Vano L, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. The lancet Psychiatry. 2020;7(1):64-77. doi: 10.1016/s2215-0366(19)30416-x

Ko YK, Soh MA, Kang SH, et al. The prevalence of metabolic syndrome in schizophrenic patients using antipsychotics. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. 2013;11(2):80-8. doi: 10.9758/cpn.2013.11.2.80

Mackin P. Cardiac side effects of psychiatric drugs. Human psychopharmacology. 2008;23 Suppl 1:3-14. doi: 10.1002/hup.915

Gugger JJ. Antipsychotic Pharmacotherapy and Orthostatic Hypotension. CNS Drugs. 2011;25(8):659-71. doi: 10.2165/11591710-000000000-00000

Stroup TS, Gray N. Management of common adverse effects of antipsychotic medications. World psychiatry : official journal of the World Psychiatric Association (WPA). 2018;17(3):341-56. doi: 10.1002/wps.20567

Romańczyk M, Surma S, Kocyan B, et al. The risk of a blood pressure increase during treatment with selected psychotropic drugs. Arterial Hypertension. 2021;25(4):135-44. doi:

Kharb P, Mittal N, Gupta MC. Carbamazepine-induced hypertension: A rare case. Journal of pharmacology & pharmacotherapeutics. 2015;6(4):216-8. doi: 10.4103/0976-500x.171879

Handler J. Lithium and antihypertensive medication: a potentially dangerous interaction. Journal of clinical hypertension (Greenwich, Conn). 2009;11(12):738-42. doi: 10.1111/j.1751-7176.2009.00181.x

Juurlink DN, Mamdani MM, Kopp A, et al. Drug-induced lithium toxicity in the elderly: a population-based study. Journal of the American Geriatrics Society. 2004;52(5):794-8. doi: 10.1111/j.1532-5415.2004.52221.x

Stahl SM. Stahl's essential psychopharmacology: Neuroscientific basis and practical applications, 4th ed. New York, NY, US: Cambridge University Press; 2013. p.491.

Olkkola KT, Ahonen J. Midazolam and other benzodiazepines. Handbook of experimental pharmacology. 2008(182):335-60. doi: 10.1007/978-3-540-74806-9_16

Mendelson N, Gontmacher B, Vodonos A, et al. Benzodiazepine Consumption Is Associated With Lower Blood Pressure in Ambulatory Blood Pressure Monitoring (ABPM): Retrospective Analysis of 4938 ABPMs. American journal of hypertension. 2018;31(4):431-7. doi: 10.1093/ajh/hpx188

Yilmaz S, Pekdemir M, Tural U, et al. Comparison of alprazolam versus captopril in high blood pressure: a randomized controlled trial. Blood pressure. 2011;20(4):239-43. doi: 10.3109/08037051.2011.553934

Grossman E, Nadler M, Sharabi Y, et al. Antianxiety treatment in patients with excessive hypertension. American journal of hypertension. 2005;18(9 Pt 1):1174-7. doi: 10.1016/j.amjhyper.2005.03.728

Rivasi G, Kenny RA, Ungar A, et al. Effects of benzodiazepines on orthostatic blood pressure in older people. European Journal of Internal Medicine. 2020;72:73-8. doi: https://doi.org/10.1016/j.ejim.2019.10.032

Rivasi G, Rafanelli M, Mossello E, et al. Drug-Related Orthostatic Hypotension: Beyond Anti-Hypertensive Medications. Drugs & aging. 2020;37(10):725-38. doi: 10.1007/s40266-020-00796-5

Mendelson N, Gontmacher B, Vodonos A, et al. Benzodiazepine Consumption Is Associated With Lower Blood Pressure in Ambulatory Blood Pressure Monitoring (ABPM): Retrospective Analysis of 4938 ABPMs. American journal of hypertension. 2017;31(4):431-7. doi: 10.1093/ajh/hpx188

Quintero J, Gutiérrez-Casares JR, Álamo C. Molecular Characterisation of the Mechanism of Action of Stimulant Drugs Lisdexamfetamine and Methylphenidate on ADHD Neurobiology: A Review. Neurology and Therapy. 2022;11(4):1489-517. doi: 10.1007/s40120-022-00392-2

Fu D, Wu DD, Guo HL, et al. The Mechanism, Clinical Efficacy, Safety, and Dosage Regimen of Atomoxetine for ADHD Therapy in Children: A Narrative Review. Frontiers in psychiatry. 2021;12:780921. doi: 10.3389/fpsyt.2021.780921

Liang EF, Lim SZ, Tam WW, et al. The Effect of Methylphenidate and Atomoxetine on Heart Rate and Systolic Blood Pressure in Young People and Adults with Attention-Deficit Hyperactivity Disorder (ADHD): Systematic Review, Meta-Analysis, and Meta-Regression. International Journal of Environmental Research and Public Health. 2018;15(8):1789. doi:

Mick E, McManus DD, Goldberg RJ. Meta-analysis of increased heart rate and blood pressure associated with CNS stimulant treatment of ADHD in adults. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2013;23(6):534-41. doi: 10.1016/j.euroneuro.2012.06.011

Goss AJ, Kaser M, Costafreda SG, et al. Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials. The Journal of clinical psychiatry. 2013;74(11):1101-7. doi: 10.4088/JCP.13r08560

Oyesanya M, Al-Juffali N. Is modafinil an effective adjunct to standard care in the treatment of schizophrenia-spectrum disorders? BJPsych Advances. 2022;28(5):281-5. doi: 10.1192/bja.2022.36

Ferraro L, Antonelli T, O'Connor WT, et al. The antinarcoleptic drug modafinil increases glutamate release in thalamic areas and hippocampus. Neuroreport. 1997;8(13):2883-7. doi: 10.1097/00001756-199709080-00016

Hashemian SM, Farhadi T. A review on modafinil: the characteristics, function, and use in critical care. Journal of Drug Assessment. 2020;9(1):82-6. doi: 10.1080/21556660.2020.1745209

Sousa A, Dinis-Oliveira RJ. Pharmacokinetic and pharmacodynamic of the cognitive enhancer modafinil: Relevant clinical and forensic aspects. Substance Abuse. 2020;41(2):155-73. doi: 10.1080/08897077.2019.1700584